home / stock / arqt / arqt news

ARQT News and Press, Arcutis Biotherapeutics Inc. From 01/31/24

Stock Information
Company Name: Arcutis Biotherapeutics Inc.
Stock Symbol: ARQT
Market: NASDAQ
Website: arcutis.com
Menu
ARQT ARQT Quote ARQT Short ARQT News ARQT Articles ARQT Message Board
Get ARQT Alerts

News, Short Squeeze, Breakout and More Instantly...
ARQT - Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture

2024-01-31 03:09:25 ET Summary Arcutis is a late-stage biopharmaceutical company focused on developing treatments for immune-mediated dermatological diseases. The company has received FDA approval for its topical cream, Zoryve, for the treatment of plaque psoriasis and seborrheic ...
ARQT - Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial

Novel steroid-free topical foam effectively controls seborrheic dermatitis Once-daily ZORYVE ® (roflumilast) topical foam, 0.3%, is approved to treat seborrheic dermatitis in individuals 9 years of age and older WESTLAKE VILLAGE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ar...

ARQT - GDRX, SSRM and EOLS are among after hour movers

2024-01-26 16:59:28 ET Gainers: Olema Pharmaceuticals ( OLMA ) +3% . Baijiayun Group  ( RTC ) +3% . Cipher Mining ( CIFR ) +2% . Evolus,  ( EOLS ) +2% . SSR Mining  ( SSRM ) +2% . Losers: Progress Software ...

ARQT - ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States

First drug approved for seborrheic dermatitis with a new mechanism of action in over two decades available in pharmacies this week Effective, safe, and very well-tolerated steroid-free foam provides rapid disease clearance and significant reduction in itch Seborrheic dermatitis affects mo...
ARQT - ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids

New subgroup analysis from STRATUM study shows that individuals with an inadequate response, contraindication, or intolerance to steroids were 3.5 times more likely to achieve IGA Success with ZORYVE foam than an identical vehicle ZORYVE foam provided rapid and significant improvement in qu...

ARQT - Majority of Individuals with Atopic Dermatitis Improved with Arcutis' Roflumilast Cream 0.15% According to New Data from Phase 3 Program

Individual patient response data highlight 91.5% of individuals treated with roflumilast cream had a measurable improvement in Eczema Area and Severity Index (EASI) in just 4 weeks 85% achieved measurable improvement by Week 1 (the earliest timepoint measured) Data presented at the 2024 W...

ARQT - PCRX, CALM and CIFR are among after hour movers

2024-01-03 16:34:46 ET Gainers: iHeartMedia ( IHRT ) +10% . Arcutis Biotherapeutics ( ARQT ) +8% . Cipher Mining  ( CIFR ) +7% . Pacira BioSciences ( PCRX ) +6% . Argo Blockchain  ( ARBK ) +6% . Losers: Cal-Main...
ARQT - Mizuho upgrades Arcutis to buy, cites Zoryve sales

2024-01-03 10:25:39 ET More on Arcutis Biotherapeutics Arcutis Biotherapeutics: Almost There, But Needs Some Fine-Tuning Arcutis Biotherapeutics, Inc. (ARQT) Q3 2023 Earnings Call Transcript Arcutis Biotherapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation...

ARQT - Biggest stock movers today: SoFi Technologies, Bloomin' Brands and more

2024-01-03 05:29:44 ET Related stock stories: SoFi Technologies: Rapid Growth Might Be Worth The Risk Masonite And PGT Innovations: Slamming The Door Following A Big And Expensive Deal SoFi Technologies: Time To Load Up Bloomin’ Brands appoints Dave Ge...

ARQT - SOFI, GH and IBRX are among after hour movers

2024-01-02 16:55:53 ET Gainers: Bloomin' Brands ( BLMN ) +6% . Arcutis Biotherapeutics ( ARQT ) +6% . Stronghold Digital Mining ( SDIG ) +5% . Longboard Pharmaceuticals ( LBPH ) +4% . Guardant Health ( GH ) +3% . Losers: ...
Previous 10 Next 10